Clinical utility of plasma cell-free DNA (cfDNA) in diffuse gliomas for the detection of IDH1 R132H mutation
Pathology - Research and Practice · 2024
DOI: 10.1016/j.prp.2024.155571 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology - Research and Practice, 2024. Verfasst von Swati Singh und 12 weiteren Autor:innen. Beteiligte Einrichtung: Neuropathology Laboratory, All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Glioma, Mutation, Brain Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Indian Council of Medical Research.
Abstract (Originalsprache)
Liquid biopsy for CNS tumors is in its nascent phase, hindered by the low levels of circulating tumor DNA (ctDNA). Overcoming this challenge requires highly sensitive molecular techniques. DD-PCR emerges as a standout technique due to its ability to identify rare mutations, copy number variations, and circulating nucleic acids, making it one of the best methods for identifying somatic mutations in cell-free DNA (cfDNA). Despite promising results from various studies demonstrating the feasibility of obtaining informative ctDNA profiles from liquid biopsy samples, challenges persist, including the need to standardize sample collection, storage, and processing methods, define clear assay positivity thresholds, and address the overall low assay sensitivity. Our two-phase study began by assessing DD-PCR efficacy in FFPE tissues, revealing robust concordance with immunohistochemistry. In Phase 1 (85 cases), DD-PCR on FFPE tissues demonstrated 100 % sensitivity and specificity for IDH1 R132H mutations. In Phase 2 (100 cases), analysis extended to cfDNA, maintaining high specificity (100 %) with moderate sensitivity (44.2 %). Overall concordance with immunohistochemistry was 61 %, highlighting liquid biopsy's potential in glioma management. The findings emphasized DD-PCR's clinical utility in both tissue and liquid biopsy, underscoring its role in early detection, diagnosis, and therapeutic monitoring of diffuse gliomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuropathology Laboratory, All India Institute of Medical Sciences, New Delhi, India.
- Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India.
- Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
- CSIR Institute of Genomics and Integrative Biology, Delhi, India.
- Neuropathology Laboratory, All India Institute of Medical Sciences, New Delhi, India. Electronic address: surivaishali@yahoo.co.in.
Förderung
- Indian Council of Medical Research
Zitieren
APA
Singh, S., Bhardwaj, S., Dandapath, I., Singh, J., Das, S., Mohan, T., Bora, S. K., Kedia, S., Suri, A., Sharma, M. C., Sarkar, C., Faruq, M., & Suri, V. (2024). Clinical utility of plasma cell-free DNA (cfDNA) in diffuse gliomas for the detection of IDH1 R132H mutation. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2024.155571
Vancouver
Singh S, Bhardwaj S, Dandapath I, Singh J, Das S, Mohan T, et al. Clinical utility of plasma cell-free DNA (cfDNA) in diffuse gliomas for the detection of IDH1 R132H mutation. Pathology - Research and Practice. 2024. doi:10.1016/j.prp.2024.155571
BibTeX
@article{Singh2024,
author = {Singh, Swati and Bhardwaj, Supriya and Dandapath, Iman and Singh, Jyotsna and Das, Sumanta and Mohan, Trishala and Bora, Santanu Kumar and Kedia, Shweta and Suri, Ashish and Sharma, Mehar Chand and Sarkar, Chitra and Faruq, Mohammed and Suri, Vaishali},
title = {Clinical utility of plasma cell-free DNA (cfDNA) in diffuse gliomas for the detection of IDH1 R132H mutation},
journal = {Pathology - Research and Practice},
year = {2024},
doi = {10.1016/j.prp.2024.155571}
}
EUVIMED